首页> 外国专利> METHODS AND COMPOSITIONS OF 32P-LABELED ADENINE NUCLEOTIDES FOR THE TREATMENT OF ATHEROSCLEROSIS, VASCULAR ARTERIAL DISEASES AND CORONARY ARTERY DISEASES

METHODS AND COMPOSITIONS OF 32P-LABELED ADENINE NUCLEOTIDES FOR THE TREATMENT OF ATHEROSCLEROSIS, VASCULAR ARTERIAL DISEASES AND CORONARY ARTERY DISEASES

机译:[32P]标记的腺嘌呤核苷酸治疗动脉粥样硬化,血管性动脉疾病和冠状动脉疾病的方法和组成

摘要

A method for the treatment of atherosclerosis. The method includes the administration of a 32P-labeled agent as a beta emitter, such as 32P-labeled ATP or other 32P-labeled adenine nucleotides, whereby the 32P-labeled agent seeks and then permeates the atherosclerotic plaque en bloc without prior degradation. The accumulation of the 32P-labeled agent in the atherosclerotic plaque is achieved at time points whereby the 32P-labeled agent is cleared from the blood. Thus, radionuclide-labeled adenine nucleotides accumulate with high specificity in atherosclerotic lesions and in the heart. The beta particles (electrons) emitted by the 32P-label have a maximal path distance of about 0.5 cm and their energy preferentially destroy cells present in the atherosclerotic plaque without affecting vessel integrity or inducing arterial thrombosis.
机译:一种治疗动脉粥样硬化的方法。该方法包括施用32P标记的试剂作为β发射体,例如32P标记的ATP或其他32P标记的腺嘌呤核苷酸,由此32P标记的试剂寻找并随后渗透整个动脉粥样硬化斑块,而无需事先降解。在从血液中清除32P标记的药剂的时间点实现了32P标记的药剂在动脉粥样硬化斑块中的积累。因此,放射性核素标记的腺嘌呤核苷酸在动脉粥样硬化病变和心脏中以高特异性积累。由32P标签发射的β粒子(电子)的最大路径距离约为0.5厘米,其能量优先破坏存在于动脉粥样硬化斑块中的细胞,而不会影响血管的完整性或引起动脉血栓形成。

著录项

  • 公开/公告号US2012128582A1

    专利类型

  • 公开/公告日2012-05-24

    原文格式PDF

  • 申请/专利权人 ELIEZER RAPAPORT;

    申请/专利号US201113185083

  • 发明设计人 ELIEZER RAPAPORT;

    申请日2011-07-18

  • 分类号A61K51;A61P29;A61P9;A61P9/10;A61K31/7076;A61K9/127;

  • 国家 US

  • 入库时间 2022-08-21 17:33:03

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号